!!Christophe Caux - Curriculum Vitae
\\
__Education and Degrees__ 
\\
*1984 DUT, Biology, U La Rochelle\\
*1987 Ingenior & Master in Biology, U Clermont \\
*1992 PhD in Immunology, U Lyon\\
*1999 HDR U Lyon, 1999\\
*2006 INSERM Research Director
\\
__Current position__
\\
*2017 Director of Team “Cancer Immune Surveillance and Therapeutic targeting ”, CRCL\\
*2019  Director LICL, “Laboratory of Immunotherapy of Cancer of Lyon”, CLB
\\
__Academic responsibilities__
\\
*2004 - 2016 C Caux coordination of the cytometry platform\\
*2011 - 2021 Co-Director of Department “Immunity, Virus & Microenvironment” of CRCL\\
*2011 WP leader of “Tumor Immune surveillance”, LabEx DEWweCAN coordinated by P Mehlen\\
*2011 - 2022 WP Leader of “Immune surveillance & escape” LYRICan (INCa SIRIC) coordinated by JY Blay
\\
__Editorial boards__
\\
*2002 Associate editor for Journal of Leukocyte Biology \\
*2013 2018 Associate editor for Cancer Research\\
*2017 Associate editor for Bulletin du Cancer\\
*2019 Associate editor for “Cancers” and “Frontiers” 
\\
__Scientific Societies and Networks__
\\
*2012 Coordinator of LYRIC Immuno-monitoring Network in Lyon \\
*2017 Member of the UNICANCER Immuno-Oncology group\\
*2018 Coordinator of the UNICANCER Immunology Task Force\\
*2019 Founding member of the FITC French ImmunoTherapy of Cancer Society
\\
__Expertises and evaluation__
\\
*2000- Referee for and member of national and international funding agencies  (EU, ARC, ANR, Ligue, INCa, ITMO cancer…)\\
*2019- Member of the national scientific committee of “Ligue contre le Cancer”\\
*2022- Member of the INSERM scientific commission CSS2\\
*Consulting: BMS, PDC-Line, MSD , Roche, AMGEN
\\
__Conferences and meeting organization__
\\
*2012 Organisation committee of 8 international conferences\\
*2012 >60 invitations to international conferences and 10/year invited presentations and seminars\\
\\
__Teaching and PhD committees:__ 30h/year\\
\\
__Scientific production__\\
\\
Author of >190 publications in international scientific journals. H-factor: 73; 6 patents since 2009, 2 licences. (see publication list)\\
\\
Patents and valorization: filling of >20 patents within Schering-Plough and 6 from my present work in the academia:\\
Patent-2 licensing to GSK exploring anti-ICOS in human clinical trials\\
Patent-3&4: Co-authored with Innate-Pharma\\
Patent-4 licensing to the Spin-off ErVaccine \\
\\
__Major Grants and national and international Networks__\\
\\
From 2007: Coordination of 12 National INCa, 2 ANR, 3 Foundation ARC, 2 European programs\\ \\[{ALLOW view All}][{ALLOW edit ccaux}][{ALLOW upload ccaux}][{ALLOW comment All}]